Target Name: RUNX1T1
NCBI ID: G862
Other Name(s): CBFA2T1 isoform r1t1-8a58 | RUNX1 partner transcriptional co-repressor 1, transcript variant 10 | MTG8_HUMAN | CBFA2T1 isoform r1t1-7a47 | RUNX1T1 variant 1 | CBFA2T1 isoform r1t1-7a51 | CBFA2T1 isoform r1t1-7d55 | Acute myelogenous leukemia 1 translocation 1, cyclin-D related | RUNX1 partner transcriptional co-repressor 1, transcript variant 15 | CBFA2T1 isoform r1t1-7a52 | Cyclin D related protein | MTG8 | RUNX1 translocation partner 1 | RUNX1T1 variant 15 | Myeloid translocation gene on 8q22 | RUNX1T1 variant 13 | RUNX1 partner transcriptional co-repressor 1 | zinc finger MYND domain-containing protein 2 | myeloid translocation gene on 8q22 | MTG8 protein | RUNX1 partner transcriptional co-repressor 1, transcript variant 13 | RUNX1T1 variant 10 | AML1T1 | CBFA2T1 isoform r1t1-7d53 | Protein CBFA2T1 | AML1-MTG8 | CBFA2T1 isoform r1t1-11a61 | CBFA2T1 | CBFA2T1 isoform r1t1-7d56 | Eight twenty one protein | CBFA2T1 isoform r1t1-11a64 | CBFA2T1 isoform r1t1-7a50 | Protein CBFA2T1 (isoform A) | CBFA2T1 isoform r1t1-11a63 | Zinc finger MYND domain containing protein 2 | CBFA2T1 isoform r1t1-7a48 | core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related | CBFA2T1 isoform r1t1-11a65 | RUNX1 partner transcriptional co-repressor 1, transcript variant 4 | CBFA2T1 isoform r1t1-11a62 | runt-related transcription factor 1; translocated to, 1 (cyclin D-related) | Protein MTG8 | ZMYND2 | Protein CBFA2T1 (isoform C) | Protein CBFA2T1 (isoform D) | RUNX1 partner transcriptional co-repressor 1, transcript variant 5 | CBFA2T1 isoform r1t1-8a59 | runt related transcription factor 1; translocated to, 1 (cyclin D related) | CBFA2T1 isoform r1t1-8a57 | RUNX1 partner transcriptional co-repressor 1, transcript variant 1 | Protein ETO | CBFA2T1 isoform r1t1-7a49 | Runt related transcription factor 1; translocated to, 1 (cyclin D related) | Eigth twenty one protein (ETO) | Core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related | MTG8a | CBFA2T1 isoform r1t1-8a60 | CBFA2T1 isoform r1t1-7d54 | Protein CBFA2T1 (isoform B) | Cyclin-D-related protein | RUNX1T1 variant 5 | acute myelogenous leukemia 1 translocation 1, cyclin-D related | CDR | Protein CBFA2T1 (isoform F) | eight twenty one protein | Zinc finger MYND domain-containing protein 2 | ETO | RUNX1T1 variant 4

Understanding The Potential Therapeutic Applications of RUNX1T1

RUNX1T1 (CBFA2T1 isoform r1t1-8a58) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a key regulator of cell growth and differentiation, and is involved in the development and maintenance of tissues. Despite its importance, little is known about RUNX1T1 and its role in human disease. In this article, we will explore the biology and potential therapeutic applications of RUNX1T1.

Structure and Expression

RUNX1T1 is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. It is expressed in the brain at levels of 1-2% of the total cell protein and in the heart at levels of 6-12% of the total cell protein. It is also expressed in the kidneys, where it is expressed at levels of 10-20% of the total protein in the glomeruli. RUNX1T1 is a cytoplasmic protein and is mainly localized to the cytoplasm of cells.

Function and Interaction

RUNX1T1 is a key regulator of cell growth and differentiation. It is involved in the development and maintenance of tissues and is thought to play a role in the regulation of cell proliferation. RUNX1T1 has been shown to regulate the growth and differentiation of various tissues, including the brain, heart, and kidneys.

In addition to its role in cell growth and differentiation, RUNX1T1 is also involved in the regulation of cell survival. Studies have shown that RUNX1T1 can induce cell apoptosis in response to various stressors, such as chemotherapy drugs and UV radiation. This suggests that RUNX1T1 may have potential as a therapeutic target for diseases that are characterized by cell dysfunction and death.

Potential Therapeutic Applications

RUNX1T1 has the potential to be a therapeutic target for a variety of diseases. Its role in cell growth and differentiation, as well as its ability to regulate cell survival, make it an attractive target for diseases that are characterized by cellular dysfunction and death.

One potential therapeutic application of RUNX1T1 is in the treatment of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and can be treated with drugs that target the production or degradation of specific proteins. Since RUNX1T1 is involved in the regulation of cell growth and differentiation, it may be a useful target for these diseases.

Another potential therapeutic application of RUNX1T1 is in the treatment of cancer. The regulation of cell growth and differentiation is a key aspect of cancer development, and RUNX1T1 may be involved in the regulation of cell proliferation in cancer cells. Therefore, RUNX1T1 may be a useful target for cancer therapies that target the regulation of cell growth and differentiation.

Conclusion

RUNX1T1 is a protein that is expressed in various tissues of the body and is involved in the regulation of cell growth and differentiation. Its role in the development and maintenance of tissues makes it an attractive target for therapeutic applications. The potential therapeutic applications of RUNX1T1 are vast and continue to be explored in the medical community. Further research is needed to fully understand the role of RUNX1T1 in disease and to develop effective therapies that target this protein.

Protein Name: RUNX1 Partner Transcriptional Co-repressor 1

Functions: Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes (PubMed:12559562, PubMed:15203199, PubMed:10688654). Can repress the expression of MMP7 in a ZBTB33-dependent manner (PubMed:23251453). Can repress transactivation mediated by TCF12 (PubMed:16803958). Acts as a negative regulator of adipogenesis (By similarity). The AML1-MTG8/ETO fusion protein frequently found in leukemic cells is involved in leukemogenesis and contributes to hematopoietic stem/progenitor cell self-renewal (PubMed:23812588)

More Common Targets

RUNX2 | RUNX2-AS1 | RUNX3 | RUNX3-AS1 | RUSC1 | RUSC1-AS1 | RUSC2 | RUSF1 | RUVBL1 | RUVBL1-AS1 | RUVBL2 | RWDD1 | RWDD2A | RWDD2B | RWDD3 | RWDD3-DT | RWDD4 | RXFP1 | RXFP2 | RXFP3 | RXFP4 | RXRA | RXRB | RXRG | RXYLT1 | Ryanodine receptor | RYBP | RYK | RYR1 | RYR2 | RYR3 | RZZ complex | S100 Calcium Binding Protein | S100A1 | S100A10 | S100A11 | S100A11P1 | S100A12 | S100A13 | S100A14 | S100A16 | S100A2 | S100A3 | S100A4 | S100A5 | S100A6 | S100A7 | S100A7A | S100A7L2 | S100A7P1 | S100A8 | S100A9 | S100B | S100G | S100P | S100PBP | S100Z | S1PR1 | S1PR1-DT | S1PR2 | S1PR3 | S1PR4 | S1PR5 | SAA1 | SAA2 | SAA2-SAA4 | SAA3P | SAA4 | SAAL1 | SAC3D1 | SACM1L | SACS | SACS-AS1 | SAE1 | SAFB | SAFB2 | SAG | SAGA complex | SAGE1 | SALL1 | SALL2 | SALL3 | SALL4 | SALL4P7 | SALRNA2 | SAMD1 | SAMD10 | SAMD11 | SAMD12 | SAMD12-AS1 | SAMD13 | SAMD14 | SAMD15 | SAMD3 | SAMD4A | SAMD4A-AS1 | SAMD4B | SAMD5 | SAMD7 | SAMD8